Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776331 | 0.88 | CALM1 (0.57) | CA12CA1CA2CA9CA14 | |
| SCHEMBL3076344 | 0.84 | APP (0.57) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL3079479 | 0.82 | CA12 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6069559 | 0.82 | CALM1 (0.60) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL8495791 | 0.82 | FFAR1 (0.52) | CA12CA1CA2CA9CA14 | |
| SCHEMBL3080258 | 0.77 | APP (0.67) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL97063 | 0.77 | CYP1A2 (0.52) | CA12CA1CA2CA9CYP1A1 | |
| SCHEMBL198432 | 0.77 | CALM1 (0.75) | CA12CA1CA2CA9CA14 | |
| SCHEMBL14584300 | 0.76 | FFAR1 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL5150258 | 0.76 | FFAR1 (0.50) | FFAR1FFAR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20050181984-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY | 2005-08-18 | — | — | US | disclosed |
| US-6916784-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2005-07-12 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030220236-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY | 2003-11-27 | — | — | US | disclosed |
| EP-0561639-B1 | Cyclic peptide antifungal agents and process for preparation thereof | LILLY CO ELI (US) | 2002-05-15 | — | — | EP | disclosed |
| US-5965525-A | FOR INHIBITING FUNGAL AND PARASITIC ACTIVITIES | ELI LILLY AND COMPANY (US) | 1999-10-12 | — | — | US | disclosed |
| CN-1036715-C | Cyclic peptide antifungal agents and process for preparation thereof | LILLY CO ELI (US) | 1997-12-17 | — | — | CN | disclosed |
| CN-1080926-A | Cyclic peptide antifungal agents and preparation method thereof | LILLY CO ELI (US) | 1994-01-19 | — | — | CN | disclosed |
| EP-0561639-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 1993-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220236-A1 | Cyclic peptide antifungal agents and process for preparation thereof | NGLY1, HM13, PTMS | CA12 4346/4885CA1 2248/4885CA2 2853/4885 |
| US-20050181984-A1 | Cyclic peptide antifungal agents and process for preparation thereof | NGLY1, PTMS, HM13 | CA12 4368/4885CA1 2039/4885CA2 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.